ERBB2 and colorectal carcinoma: However, in the efforts to distinguish patients who really would benefit from anti-HER2 agents, they emphasized the importance of performing HER2 assessment on surgical specimens rather than on biopsy ones in order to avoid HER2 false positivity due to HER2 heterogeneous expression in CRC cells [110].